Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Zelnecirnon (RPT193) in Healthy Volunteers and Atopic Dermatitis
NCT04271514Phase 1Completed
- Sponsor
- RAPT Therapeutics
- Start
- Aug 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of zelnecirnon in atopic dermatitis (AD) (6 arms), sponsored by RAPT Therapeutics. Primary endpoint: Incidence of Treatment Emergent Adverse Events. Started Aug 2019; status: completed.
02
Drugs
zelnecirnon
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04271514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04271514.